GlassScriptPhysician profile
Justin Morar
NPI 1043604614
$7,032.65
in general payments reported to CMS, 2019-2025
57 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $516 · 2021: $558 · 2022: $1,363 · 2023: $1,112 · 2024: $1,306 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,742.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,003.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $929.42 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $731.84 | 2019-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Pfizer INC. | $726.99 | 2019-2025 | |
| Lilly USA, LLC | $617.10 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $360.64 | 2019-2025 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.65 | 2020-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.36 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $181.65 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $147.86 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $144.47 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $126.44 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $121.62 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $99.96 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $84.79 | 2021 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Morar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.